52 Week Range
As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Kintor Pharma Says Unit Entered Proxalutamide Licensing Agreement
JPMorgan Chase & Co's Long Position In Shanghai Fosun Pharma Falls To 4.69% - HKEX Filing
Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.
Building A, No. 1289 Yishan Road
Chairman of the Board, Chief Executive Officer, Executive Director
Chief Financial Officer, Executive President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Chinese regulators have completed an expert review of a COVID-19 mRNA vaccine developed by Germany's BioNTech and Fosun Pharma and the shot is in the administration review stage, Caixin reported, citing the Chinese company.
China's Shanghai Fosun Pharmaceutical said its subsidiary has agreed to provide a factory with an annual capacity to make up to 1 billion doses of the COVID-19 vaccine developed by BioNTech .
China's Shanghai Fosun Pharmaceutical said on Sunday its subsidiary had agreed to set up a joint venture with BioNTech for the manufacture and commercialisation of the German firm's COVID-19 vaccine.
Hong Kong has formally approved use of the Fosun Pharma-BioNTech vaccine, the city government said on Monday, the first COVID-19 vaccine to be accepted in the Asian financial hub.
Shanghai Fosun Pharmaceutical Group is planning a facility in China to produce the COVID-19 vaccine developed by Germany's BioNTech , financial magazine Caixin reported on Wednesday.
Shanghai Fosun Pharmaceutical Group will set up a joint venture with Germany's BioNTech to produce COVID-19 vaccines in China, financial magazine Caixin reported on Wednesday.
Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China's National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.